The European Commissioner for Science and Research, Janez Potocnik, has officially launched the network of European Researchers in Japan. Consulted through an on-line survey, the European researchers working in Japan have pronounced themselves very much in favor of this network (74% of the respondents) and expressed their specific needs: to develop their contacts and get access to information on career development, research funding and Europe-Japan cooperation opportunities. The tool set up for them by the European Commission will answer these needs with interactive tools of information and networking.
"European researchers working in Japan represent a patrimony of knowledge and experience. They are the Ambassadors of European research in Japan and this network will be an important tool for reinforcing research collaboration between Europe and Japan," stated Commissioner Potocnik.
Japan and the EU together accounts for about 40% of the world's Gross Domestic Product and are amongst each other's main trade and investment partners. Both partners are convinced that research and innovation are at the heart of a successful strategy to address the challenges of industrial competitiveness and sustainable development. As part of this strategy, researchers represent a golden resource that should benefit from specific facilities to network and identify professional opportunities, according to a European Commission statement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze